Daewon Pharmaceutical Co., Ltd(KR:003220)
₩7,810.00-10.00 (-0.13%)
KR:003220
Daewon Pharmaceutical Co., Ltd financials statements
₩7,810.00
At close:-10.00 (-0.13%)
Want to see KR:003220 full AI Analyst Report?
Daewon Pharmaceutical Co., Ltd (003220) Income Statement
Daewon Pharmaceutical Co., Ltd Income Statement
Last quarter (Q2 2026), Daewon Pharmaceutical Co., Ltd's total revenue was ₩152.83B, an increase of 6.24% from the same quarter last year. In Q2, Daewon Pharmaceutical Co., Ltd's net income was ₩4.03B. See Daewon Pharmaceutical Co., Ltd’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| ₩ 605.64B | ₩ 598.16B | ₩ 526.95B | ₩ 478.88B | ₩ 354.18B | |
| ₩ 266.09B | ₩ 287.33B | ₩ 254.23B | ₩ 237.94B | ₩ 176.47B | |
| ₩ 262.61B | ₩ 259.11B | ₩ 222.00B | ₩ 194.94B | ₩ 157.04B | |
| Depreciation and Amortization | ₩ 23.74B | ₩ 20.09B | ₩ 17.56B | ₩ 19.37B | ₩ 17.81B |
| ₩ 27.23B | ₩ 45.56B | ₩ 48.01B | ₩ 61.77B | ₩ 37.11B | |
| ₩ 3.48B | ₩ 28.22B | ₩ 32.23B | ₩ 43.01B | ₩ 19.43B | |
| ₩ -734.01M | ₩ -13.03B | ₩ -6.40B | ₩ -4.28B | ₩ -2.29B | |
| ₩ 2.75B | ₩ 15.19B | ₩ 25.83B | ₩ 38.72B | ₩ 17.14B | |
| ₩ -1.38B | ₩ 14.21B | ₩ 23.92B | ₩ 31.94B | ₩ 6.99B | |
| Per Share Metrics | |||||
| Basic EPS | ₩ -64.37 | ₩ 665.84 | ₩ 1139.91 | ₩ 1509.75 | ₩ 329.36 |
| Diluted EPS | ₩ -64.37 | ₩ 655.37 | ₩ 1104.19 | ₩ 1478.37 | ₩ 329.36 |
| Weighted Average Shares Outstanding | 21.45M | 21.29M | 20.98M | 21.16M | 21.22M |
| Weighted Average Shares Outstanding (Diluted) | 21.45M | 21.66M | 21.66M | 21.88M | 21.22M |
Currency in KRW
